Special Report: How Are Novel Follow-On Therapies Impacting Multiple Sclerosis Treatment Paradigms in the United States? is designed to assess and quantify the market impact of the 2014 launches of Teva’s Copaxone 40 mg three-times-weekly (3TW) and Biogen Idec’s Plegridy for the treatment of relapsing forms of multiple sclerosis (MS). Along with trial, adoption, and uptake of these disease-modifying therapies (DMTs), the report assesses U.S. neurologists’ perceptions on the uniqueness and drivers of preferential prescribing of Copaxone 40 mg 3TW and Plegridy compared with other marketed DMTs. With a potential launch of generic glatiramer acetate (GA) occurring in the next year, neurologists are also surveyed about its likely effect on MS prescribing decisions and the competitive landscape.
Questions Answered in This Report:
- Teva launched Copaxone 40 mg 3TW in the United States in February 2014. Biogen Idec’s Plegridy entered the U.S. market in November 2014. What is the current trial and uptake of Copaxone 40 mg 3TW and Plegridy among neurologists? Where in the treatment algorithm are the products being incorporated? Which DMTs have been most impacted by the adoption of the new products? Have neurologists faced reimbursement challenges when attempting to prescribe the novel follow-on therapies? What cost-control mechanisms are most commonly imposed? What are current obstacles to increased use of Copaxone 40 mg 3TW and Plegridy?
- The novel follow-on therapies seek to leverage neurologists’ longstanding comfort with Copaxone 20 mg and Avonex, while offering improvement on dosing attributes relative to the predecessor drugs. How does Copaxone 40 mg 3TW compare with Copaxone 20 mg on attributes of clinical importance to neurologists? How does Plegridy compare with Avonex? How does the clinical performance of the novel follow-on therapies compare with the array of marketed DMTs for MS?
- Biogen Idec has several products approved for MS, which are entrenched across the treatment algorithm. Teva’s Copaxone 20 mg is a longstanding treatment mainstay facing the looming threat of generic competition. What promotional messages and activities are Biogen Idec and Teva employing in support of their novel products? Do neurologists believe Teva and Biogen Idec could be doing more to drive uptake of Copaxone 40 mg 3TW and Plegridy, respectively?
- The potential U.S. entry of generic GA 20 mg would raise numerous clinical and market access issues that could impact early lines of treatment in MS. How comfortable are neurologists with prescribing generic GA 20 mg? In which clinical scenarios do they expect to prescribe it? How will generic GA 20 mg impact neurologists’ anticipated prescribing of MS DMTs one year from now?
Markets covered: United States.
Primary research: 104 neurologists surveyed; 12 qualitative interviews with a subset of survey respondents.
Indication coverage: Relapsing-remitting MS.